Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Xoma ( (XOMA) ) is now available.
On October 3, 2025, XOMA Royalty Corporation entered into two ‘at the market’ sales agreements to offer and sell up to $75 million in common stock through Leerink Partners LLC and up to $50 million in depositary shares through H.C. Wainwright & Co., LLC. These agreements allow XOMA to sell shares directly on Nasdaq or other trading markets, with the intention of using proceeds for acquiring additional royalty and milestone revenue streams, working capital, and general corporate purposes. Both agreements allow for termination by either party and include customary representations, warranties, and indemnification rights.
The most recent analyst rating on (XOMA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Xoma’s overall stock score reflects a blend of positive technical momentum and strategic corporate developments, offset by financial challenges and valuation concerns. The merger with Turnstone Biologics is a significant positive factor, while the negative P/E ratio and profitability issues weigh on the score.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
Average Trading Volume: 50,292
Technical Sentiment Signal: Buy
Current Market Cap: $474.2M
See more insights into XOMA stock on TipRanks’ Stock Analysis page.